We’re proud to share the LinkedIn post from our CEO, Cedric Bogaert, following CureVac’s announcement of U.S. FDA clearance to initiate a Phase 1 clinical trial for an mRNA-based immunotherapy targeting squamous non-small cell lung cancer (sqNSCLC). The clinical...
myNEO Therapeutics will attend job fairs and participate in the following events: Biotech Showcase JPM Healthcare conference 2025 – San Francisco, USA – January 13-January 16, 2025 Keystone Symposia RNA Medicated Regulation of Immunity: Mechanism, Disease and...
We are thrilled to announce that myNEO Therapeutics has partnered with the University of Liverpool to launch a groundbreaking Phase 1 clinical trial focused on developing a personalised therapeutic cancer vaccine for patients with Non-Small Cell Lung Cancer (NSCLC)....
Our CEO, Cedric Bogaert, shares exciting news: “I’m glad to share the latest results of our CAMYO-01 program (shared colorectal cancer vaccine) with LinkedIn as well. We’ve presented these results in the past month on several scientific conferences,...
🚀 Advancing Immunotherapy through Antigen Target ScreeningWe’re excited to announce the creation of an innovative antigen target library, built from extensive screenings across 1,000+ patients with diverse cancer indications. This well-validated library is one of the...
Our CEO, Cedric Bogaert, shares exciting news:“Happy to provide insight into a secondary program we’ve applied our focus and technology to. Pancreatic cancer has been and continues to be one of the deadliest tumors (only 12% survival in 5 years), and targets are...
